Klaus Orlinger's most recent trade in Hookipa Pharma Inc was a trade of 367,300 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Hookipa Pharma Inc | Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 367,300 | 367,300 | - | - | Stock Option (Right to Buy) | |
| Hookipa Pharma Inc | Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 194,200 | 194,200 | - | - | Stock Option (Right to Buy) | |
| Hookipa Pharma Inc | Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 48,350 | 48,350 | - | - | Stock Option (Right to Buy) | |
| Hookipa Pharma Inc | Klaus Orlinger | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 12,654 | 12,654 | - | - | Stock Option (Right to Buy) | |
| Hookipa Pharma Inc | Klaus Orlinger | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 9,188 | 10,404 (0%) | 0% | 3 | 27,564 | Common Stock |
| Hookipa Pharma Inc | Klaus Orlinger | Sr. VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 26,050 | 26,050 | - | - | Stock Option (Right to Buy) |